Effects of bisoprolol in patients with stable congestive heart failure.

AIM OF THE STUDY To analyze the effect of bisoprolol in patients with stable congestive heart failure and who tolerated beta-blockers. MATERIAL AND METHODS Two hundred and one patients performed before and 3 months after maximal tolerated doses of bisoprolol have been reached, a clinical evaluation, an echocardiography, a radionuclide angiography, a cardiopulmonary exercise test and hormonal determinations. RESULTS Mean dose of bisoprolol was 8.8 +/- 2.4 mg/d. Patients had a significant improvement in NYHA classification. Heart rate at rest decreased from 87 +/- 17 to 66 +/- 12 beats/min (P < 0.0001) without any effect on electrocardiographic parameters. Left ventricular ejection fraction improved from 31 +/- 11 to 41 +/- 13% (P < 0.0001), with a significant decrease in end-diastolic and end-systolic left ventricle diameters and volumes. Mitral profile improved. Peak VO2 increased from 16.1 +/- 5 to 16.8 +/- 5.5 ml/min/kg (P = 0.001) with a significant increase in O2 pulse (from 8.52 +/- 2.7 to 11.2 +/- 3.5 ml/min/beats, P < 0.0001). Plasma levels of A-type and of B-type natriuretic peptides and of norepinephrine significantly decreased after bisoprolol. CONCLUSIONS Bisoprolol significantly improved left ventricle ejection fraction with a reverse remodeling of the left ventricle, a decrease in hormonal activation and a modest improvement in exercise capacity.

[1]  Effect of carvedilol on survival in severe chronic heart failure. , 2001 .

[2]  B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. , 2004, Journal of the American College of Cardiology.

[3]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[4]  M. Guazzi,et al.  Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. , 2002, Chest.

[5]  Matthias Stuber,et al.  Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. , 2002, American heart journal.

[6]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[7]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[8]  P. De Groote,et al.  Plasma levels of endothelin-1 at rest and after exercise in patients with moderate congestive heart failure. , 1995, International journal of cardiology.

[9]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[10]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[11]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[12]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[13]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[14]  M. Hetzel,et al.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). , 1997, Circulation.

[15]  J. Le Heuzey,et al.  Effects of bisoprolol on heart rate variability in heart failure. , 1996, The American journal of cardiology.

[16]  D. Renlund,et al.  Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.

[17]  P. De Groote,et al.  Plasma levels of atrial natriuretic peptide at peak exercise: a prognostic marker of cardiovascular-related death and heart transplantation in patients with moderate congestive heart failure. , 1997, The Journal of Heart and Lung Transplantation.

[18]  P. Grayburn,et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.

[19]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[20]  X Marchandise,et al.  Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. , 1998, Journal of the American College of Cardiology.

[21]  M. Packer,et al.  Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. , 1998, Circulation.

[22]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.